Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy. Front Immunol 2016;7:176
Date
06/01/2016Pubmed ID
27242783Pubmed Central ID
PMC4863891DOI
10.3389/fimmu.2016.00176Scopus ID
2-s2.0-84973571081 (requires institutional sign-in at Scopus site) 26 CitationsAbstract
Receptors on T and NK cells systematically propagate highly complex signaling cascades that direct immune effector functions, leading to protective immunity. While extensive studies have delineated hundreds of signaling events that take place upon receptor engagement, the precise molecular mechanism that differentially regulates the induction or repression of a unique effector function is yet to be fully defined. Such knowledge can potentiate the tailoring of signal transductions and transform cancer immunotherapies. Targeted manipulations of signaling cascades can augment one effector function such as antitumor cytotoxicity while contain the overt generation of pro-inflammatory cytokines that contribute to treatment-related toxicity such as "cytokine storm" and "cytokine-release syndrome" or lead to autoimmune diseases. Here, we summarize how individual signaling molecules or nodes may be optimally targeted to permit selective ablation of toxic immune side effects.
Author List
Rajasekaran K, Riese MJ, Rao S, Wang L, Thakar MS, Sentman CL, Malarkannan SAuthors
Subramaniam Malarkannan PhD Professor in the Medicine department at Medical College of WisconsinSridhar Rao MD, PhD Associate Professor in the Pediatrics department at Medical College of Wisconsin